Celltrion’s Herzuma receives ‘recommendation for approval’ from European CHMP

On the 15^th(local time), Celltrion announced to acquire ‘recommendation for approval’ on all the indications for ‘Herzuma(generic name: trastuzumab, development name: CT-P6),’ an antibody biosimilar for the treatment of breast cancer, from the Committee for Medicinal Products for Human Use(CHMP) under the European Medicines Agency(EMA).

Herzuma, an antibody biosimilar for the treatment of brea...